Jackson Edwin K, Mi Zaichuan
Department of Pharmacology, Center for Clinical Pharmacology, University of Pittsburgh, School of Medicine, PA 15219, USA.
Hypertension. 2008 Jun;51(6):1637-42. doi: 10.1161/HYPERTENSIONAHA.108.112532. Epub 2008 Apr 28.
Dipeptidyl peptidase IV converts neuropeptide Y(1-36) (Y(1)-receptor agonist released from renal sympathetic nerves) to neuropeptide Y(3-36) (selective Y(2)-receptor agonist). Previous studies suggest that Y(1), but not Y(2), receptors enhance renovascular responses to angiotensin II in kidneys from genetically-susceptible animals. Therefore, we hypothesized that inhibition of dipeptidyl peptidase IV with sitagliptin (antidiabetic drug) would augment the ability of exogenous and endogenous neuropeptide Y(1-36) to enhance renal vascular responses to angiotensin II in kidneys from spontaneously hypertensive rats. This hypothesis was tested using 3 protocols in isolated perfused kidneys. Results from Protocol 1: Exogenous neuropeptide Y(1-36) enhanced renovascular responses to angiotensin II. This effect of neuropeptide Y(1-36) was blocked by BIBP3226 (selective Y(1) receptor antagonist); Exogenous neuropeptide Y(3-36) did not enhance renovascular responses to angiotensin II. Results from Protocol 2: Sitagliptin augmented the ability of exogenous neuropeptide Y(1-36) to enhance renovascular responses to angiotensin II. This effect of sitagliptin was blocked by BIBP3226. Results from Protocol 3: Renal sympathetic nerve stimulation enhanced renovascular responses to angiotensin II; this enhancement was augmented by sitagliptin and abolished by BIBP3226. Neuropeptide Y(1-36) via Y(1) receptors enhances renovascular responses to angiotensin II in kidneys from genetically hypertensive animals. Sitagliptin, by blocking dipeptidyl peptidase IV, prevents metabolism of neuropeptide Y(1-36) and thereby increases the effects of neuropeptide Y(1-36) released from renal sympathetic nerves on Y(1) receptors leading to augmentation of neuropeptide Y(1-36)-induced enhancement of the renovascular effects of angiotensin II. The renal effects of dipeptidyl peptidase IV inhibitors in hypertensive diabetic patients merit a closer examination.
二肽基肽酶IV将神经肽Y(1 - 36)(从肾交感神经释放的Y(1)受体激动剂)转化为神经肽Y(3 - 36)(选择性Y(2)受体激动剂)。先前的研究表明,在基因易感性动物的肾脏中,Y(1)受体而非Y(2)受体可增强肾血管对血管紧张素II的反应。因此,我们推测用西他列汀(抗糖尿病药物)抑制二肽基肽酶IV会增强外源性和内源性神经肽Y(1 - 36)在自发性高血压大鼠肾脏中增强肾血管对血管紧张素II反应的能力。在离体灌注肾脏中使用3种方案对该假设进行了检验。方案1的结果:外源性神经肽Y(1 - 36)增强了肾血管对血管紧张素II的反应。神经肽Y(1 - 36)的这种作用被BIBP3226(选择性Y(1)受体拮抗剂)阻断;外源性神经肽Y(3 - 36)未增强肾血管对血管紧张素II的反应。方案2的结果:西他列汀增强了外源性神经肽Y(1 - 36)增强肾血管对血管紧张素II反应的能力。西他列汀的这种作用被BIBP3226阻断。方案3的结果:肾交感神经刺激增强了肾血管对血管紧张素II的反应;这种增强作用被西他列汀增强并被BIBP3226消除。神经肽Y(1 - 36)通过Y(1)受体增强了基因性高血压动物肾脏中肾血管对血管紧张素II的反应。西他列汀通过阻断二肽基肽酶IV,防止神经肽Y(1 - 36)的代谢,从而增加了从肾交感神经释放的神经肽Y(1 - 36)对Y(1)受体的作用,导致神经肽Y(1 - 36)诱导的血管紧张素II肾血管效应增强。二肽基肽酶IV抑制剂在高血压糖尿病患者中的肾脏效应值得进一步研究。